Literature DB >> 9146847

Single dose pharmacokinetics of oral artemether in healthy Malaysian volunteers.

M N Mordi1, S M Mansor, V Navaratnam, W H Wernsdorfer.   

Abstract

AIMS: To determine the pharmacokinetics of artemether (ARM) and its principal active metabolite, dihydroartemisinin (DHA) in healthy volunteers.
METHODS: Six healthy male Malaysian subjects were given a single oral dose of 200 mg artemether. Blood samples were collected to 72 h. Plasma concentrations of the two compounds were measured simultaneously by reversed-phase h.p.l.c. with electro-chemical detection in the reductive mode.
RESULTS: Mean (+/- s.d.) maximum concentrations of ARM, 310 +/- 153 micrograms l-1, were reached 1.88 +/- 0.21 h after drug intake. The mean elimination half-life was 2.00 +/- 0.59 h, and the mean AUC 671 +/- 271 micrograms l-1 h. The mean Cmax of DHA, 273 +/- 64 micrograms l-1 was observed at 1.92 +/- 0.13 h. The mean AUC of DHA was 753 +/- 233 micrograms h l-1'. ARM and DHA were stable at < or = -20 degrees C for at least 4 months in plasma samples.
CONCLUSIONS: The relatively short half-life of ARM may be one of the factors responsible for the poor radical cure rate of falciparum malaria with regimens employing daily dosing. In view of the rapid loss of DHA in plasma samples held at room temperature (26 degrees C) it is recommended to store them at a temperature of < or = -20 degrees C as early as possible after sample collection.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9146847      PMCID: PMC2042754          DOI: 10.1046/j.1365-2125.1997.00573.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  17 in total

Review 1.  Combination chemotherapy of schistosomiasis in laboratory studies and clinical trials.

Authors:  Jürg Utzinger; Jennifer Keiser; Xiao Shuhua; Marcel Tanner; Burton H Singer
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

2.  Population pharmacokinetics and therapeutic response of CGP 56697 (artemether + benflumetol) in malaria patients.

Authors:  F Ezzet; R Mull; J Karbwang
Journal:  Br J Clin Pharmacol       Date:  1998-12       Impact factor: 4.335

3.  Pharmacokinetics of a novel sublingual spray formulation of the antimalarial drug artemether in healthy adults.

Authors:  Sam Salman; Daryl Bendel; Toong C Lee; David Templeton; Timothy M E Davis
Journal:  Antimicrob Agents Chemother       Date:  2015-03-23       Impact factor: 5.191

Review 4.  Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine.

Authors:  N J White; M van Vugt; F Ezzet
Journal:  Clin Pharmacokinet       Date:  1999-08       Impact factor: 6.447

5.  A comparison of oral artesunate and artemether antimalarial bioactivities in acute falciparum malaria.

Authors:  Y Suputtamongkol; P N Newton; B Angus; P Teja-Isavadharm; D Keeratithakul; M Rasameesoraj; S Pukrittayakamee; N J White
Journal:  Br J Clin Pharmacol       Date:  2001-12       Impact factor: 4.335

6.  Comparative pharmacokinetics of intramuscular artesunate and artemether in patients with severe falciparum malaria.

Authors:  T T Hien; T M E Davis; L V Chuong; K F Ilett; D X T Sinh; N H Phu; C Agus; G M Chiswell; N J White; J Farrar
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

7.  Absence of significant pharmacokinetic and pharmacodynamic interactions between artemether and quinoline antimalarials.

Authors:  K Na-Bangchang; J Karbwang; R Ubalee; A Thanavibul; S Saenglertsilapachai
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2000 Jul-Dec       Impact factor: 2.441

8.  The contribution of the enzymes CYP2D6 and CYP2C19 in the demethylation of artemether in healthy subjects.

Authors:  M A van Agtmael; C A Van Der Graaf; T K Dien; R P Koopmans; C J van Boxtel
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Jul-Sep       Impact factor: 2.441

9.  Concomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lumefantrine in healthy volunteers.

Authors:  Liusheng Huang; Sunil Parikh; Philip J Rosenthal; Patricia Lizak; Florence Marzan; Grant Dorsey; Diane Havlir; Francesca T Aweeka
Journal:  J Acquir Immune Defic Syndr       Date:  2012-11-01       Impact factor: 3.731

10.  Development and validation of a high-performance liquid chromatography/tandem mass spectrometry method for the determination of artemether and its active metabolite dihydroartemisinin in human plasma.

Authors:  Liusheng Huang; Anura L Jayewardene; Xiaohua Li; Florence Marzan; Patricia S Lizak; Francesca T Aweeka
Journal:  J Pharm Biomed Anal       Date:  2009-07-07       Impact factor: 3.935

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.